3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a volatile start to the second quarter for many ...
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company ...
Vertex Pharmaceuticals: Buy, Sell, or Hold?
Vertex Pharmaceuticals has become a big name in cystic fibrosis (CF) treatments. And that's where the company makes its money ...
Buy Rating Affirmed: Vertex Pharmaceuticals’ Strategic Acquisition and Market Positioning Promise Growth
Leerink Partners analyst David Risinger has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. David Risinger has ...
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
The drugmaker isn't stopping. Vertex is moving forward with another investigational medicine that could become a big deal ...
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals
Analysts have set 12-month price targets for Vertex Pharmaceuticals, revealing an average target of $453.25, a high estimate ...
Vertex Pharmaceuticals’ Hold Rating: Balancing Cystic Fibrosis Success with Uncertain Growth from New Acquisition
Maxim Group analyst Naz Rahman has maintained their neutral stance on VRTX stock, giving a Hold rating yesterday. Naz Rahman has given his ...
Zacks.com on MSN8d
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $397.58, marking a -1.71% move from the previous day. This change lagged the S&P 500's 0.95% loss on the day. At the same time, ...
Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Vertex Pharmaceuticals (VRTX) to acquire Alpine Immune Sciences (ALPN) for $4.9b in cash. Check out why I think this deal may ...
5 Things to Know Before the Stock Market Opens
U.S. stocks futures are edging lower after a Wednesday sell-off fueled by hot inflation data, Alpine Immune Sciences is ...